BOLD

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Hornby ZacharyDirector, Officer: President & CEO $756k600k shares Grant / ExerciseJan 23, 2026 $756.0K600k shares $1.26 --
Doebele RobertChief Medical Officer $290k230k shares Grant / ExerciseJan 23, 2026 $289.8K230k shares $1.26 --
Hassig ChristianChief Scientific Officer $290k230k shares Grant / ExerciseJan 23, 2026 $289.8K230k shares $1.26 --
Oien JessicaSee Remarks $277k220k shares Grant / ExerciseJan 23, 2026 $277.2K220k shares $1.26 --
Hinkle David ASee Remarks $176k140k shares Grant / ExerciseJan 23, 2026 $176.4K140k shares $1.26 --
Brennan ChristineDirector $16k16k shares Grant / ExerciseJun 23, 2025 $16.5K16k shares $1.03 --

News

globenewswire.comBoundless Bio Reports First Quarter 2026 Financial Results and Business Highlightsglobenewswire.comMay 8

globenewswire.comBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meetingglobenewswire.comApr 17

globenewswire.comNurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategyglobenewswire.comApr 1

seekingalpha.comBoundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degraderseekingalpha.comMar 20

globenewswire.comBoundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026globenewswire.comMar 17

Trade BOLD

About Boundless Bio, Inc.

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

CEO: Zachary Hornby
IPO Date: Jul 20, 2016

Market Data

Open: $1.39
High: $1.41
Low: $1.39
Volume: 33.8K
52W High: $1.68
52W Low: $0.961

Valuation

Market Cap: $31M
Enterprise Value: $62M

Financials

Free Cash Flow: $-47M
Revenue: $0
Net Income: $-58M
Cash: $18M
Debt: $49M

Events

EarningsAug 4

EPS est. -0.6